The nuclear receptor steroidogenic factor 1 (SF-1 or NR5A1) and the zinc finger protein GATA4 mediate key events in the early steps of gonadal development and sex differentiation, presumably by activating the expression of essential target genes. An important SF-1 target in male sex differentiation is the gene encoding the anti-Müllerian hormone (AMH), which induces regression of the Müllerian ducts in the developing male embryo. In cell transfection studies, there is apparent cooperation between GATA4 and SF-1 in the regulation of both human and mouse Amh promoters. We hypothesized that compound haploinsufficiency of both SF-1 and GATA4, by reducing their synergism, might cause a more severe phenotype than that seen in mice that were heterozygous for either SF-1 or Gata4 alone. Surprisingly, in adult and embryonic mice, compound haploinsufficiency of SF-1 and GATA4 caused no gonadal or reproductive abnormalities beyond those seen in SF-1+/– mice. Thus, although cooperation between SF-1 and GATA4 very likely is important for regulation of their target genes, such synergy was not revealed in our in vivo studies of gonadal development and function.

Keywords:
AMH, GATA4, Gonadogenesis, Sexual development, SF-1, Testosterone
1.
Achermann JC, Ito M, Ito M, Hindmarsh PC, Jameson JL: A mutation in the gene encoding steroidogenic factor-1 causes XY sex reversal and adrenal failure in humans. Nat Genet 22:125–126 (1999).
2.
Achermann JC, Ozisik G, Ito M, Orun UA, Harmanci K, et al: Gonadal determination and adrenal development are regulated by the orphan nuclear receptor steroidogenic factor-1, in a dose-dependent manner. J Clin Endocrinol Metab 87:1829–1833 (2002).
3.
Arango NA, Lovell-Badge R, Behringer RR: Targeted mutagenesis of the endogenous mice Mis gene promoter: in vivo definition of genetic pathways of vertebrate sexual development. Cell 99:409–419 (1999).
4.
Bland ML, Jamieson CA, Akana SF, Bornstein SR, Eisenhofer G, et al: Haploinsufficiency of steroidogenic factor-1 in mice disrupts adrenal development leading to an impaired stress response. Proc Natl Acad Sci USA 97:14488–14493 (2000).
5.
Bland ML, Fowkes RC, Ingraham HA: Differential requirement for steroidogenic factor-1 gene dosage in adrenal development versus endocrine function. Mol Endocrinol 18:941–952 (2004).
6.
Chaboissier MC, Kobayashi A, Vidal VI, Lutzkendorf S, van de Kant HJ, et al: Functional analysis of Sox8 and Sox9 during sex determination in the mouse. Development 131:1891–1901 (2004).
7.
Correa RV, Domenice S, Bingham NC, Billerbeck AE, Rainey WE, et al: A microdeletion in the ligand binding domain of human steroidogenic factor 1 causes XY sex reversal without adrenal insufficiency. J Clin Endocinol Metab 89:1767–1772 (2004).
8.
Garg V, Kathiriya IS, Barnes R, Schluterman MK, King IN, et al: GATA4 mutations cause human congenital heart defects and reveal an interaction with TBX5. Nature 424:443–447 (2003).
9.
Giuili G, Shen WH, Ingraham HA: The nuclear receptor SF-1 mediates sexually dimorphic expression of Mullerian Inhibiting Substance, in vivo. Development 124:1799–1807 (1997).
10.
Haarer B, Viggiano S, Hibbs MA, Troyanskaya OG, Amberg DC: Modeling complex genetic interactions in a simple eukaryotic genome: actin displays a rich spectrum of complex haploinsufficiencies. Genes Dev 21:148–159 (2007).
11.
Hasegawa T, Fukami M, Sato N, Katsumata N, Sasaki G, et al: Testicular dysgenesis without adrenal insufficiency in a 46,XY patient with a heterozygous inactive mutation of steroidogenic factor-1. J Clin Endocrinol Metab 89:5930–5935 (2004).
12.
Jeyasuria P, Ikeda Y, Jamin SP, Zhao L, De Rooij DG, et al: Cell-specific knockout of steroidogenic factor 1 reveals its essential roles in gonadal function. Mol Endocrinol 18:1610–1619 (2004).
13.
Ketola I, Rahman N, Toppari J, Bielinska M, Porter-Tinge SB, et al: Expression and regulation of transcription factors GATA-4 and GATA-6 in developing mouse testis. Endocrinology 140:1470–1480 (1999).
14.
Ketola I, Pentikainen V, Vaskivuo T, Ilvesmaki V, Herva R, et al: Expression of transcription factor GATA-4 during human testicular development and disease. J Clin Endocrinol Metab 85:3925–3931 (2000).
15.
Kuo CT, Morrisey EE, Anandappa R, Sigrist K, Lu MM, et al: GATA4 transcription factor is required for ventral morphogenesis and heart tube formation. Genes Dev 11:1048–1060 (1997).
16.
Laitinen MP, Anttonen M, Ketola I, Wilson DB, Ritvos O, et al: Transcription factors GATA-4 and GATA-6 and a GATA family cofactor, FOG-2, are expressed in human ovary and sex cord-derived ovarian tumors. J Clin Endocrinol Metab 85:3476–3483 (2000).
17.
LaVoie HA: The role of GATA in mammalian reproduction. Exp Biol Med (Maywood) 228:1282–1290 (2003).
18.
LaVoie HA, McCoy GL, Blake CA: Expression of the GATA-4 and GATA-6 transcription factors in the fetal rat gonad and in the ovary during postnatal development and pregnancy. Mol Cell Endocrinol 227:31–40 (2004).
19.
Luo X, Ikeda Y, Parker KL: A cell-specific nuclear receptor is essential for adrenal and gonadal development and sexual differentiation. Cell 77:481–490 (1994).
20.
Martin LJ, Taniguchi H, Robert NM, Simard J, Tremblay JJ, Viger RS: GATA factors and the nuclear receptors, steroidogenic factor 1/liver receptor homolog 1, are key mutual partners in the regulation of the human 3beta-hydroxysteroid dehydrogenase type 2 promoter. Mol Endocrinol 19:2358–2370 (2005).
21.
Parker KL, Schimmer BP: Steroidogenic factor-1: a key determinant of endocrine development and function. Endocr Rev 18:361–377 (1997).
22.
Parker KL, Schimmer BP: Genes essential for early events in gonadal development. Ann Med 34:171–178 (2002).
23.
Rey R, Lukas-Croisier C, Lasala C, Bedecarras P: AMH/MIS: what we know already about the gene, the protein and its regulation. Mol Cell Endocrinol 211:21–31 (2003).
24.
Silverman E, Eimerl S, Orly J: CCAAT enhancer-binding protein beta and GATA-4 binding regions within the promoter of the steroidogenic acute regulatory protein (StAR) gene are required for transcription in rat ovarian cells. J Biol Chem 274:17987–17996 (1999).
25.
Tevosian SG, Albrecht KH, Crispino JD, Fujiwara Y, Eicher EM, Orkin SH: Gonadal differentiation, sex determination and normal Sry expression in mice require direct interaction between transcription partners GATA4 and FOG2. Development 129:4627–4634 (2002).
26.
Tremblay JJ, Viger RS: Transcription factor GATA-4 enhances Mullerian inhibiting substance gene transcription through a direct interaction with the nuclear receptor SF-1. Mol Endocrinol 13:1388–1401 (1999).
27.
Tremblay JJ, Viger RS: GATA factors differentially activate multiple gonadal promoters through conserved GATA regulatory elements. Endocrinology 142:977–986 (2001).
28.
Tremblay JJ, Viger RS: A mutated form of steroidogenic factor 1 (SF-1 G35E) that causes sex reversal in humans fails to synergize with transcription factor GATA-4. J Biol Chem 278:42637–42642 (2003a).
29.
Tremblay JJ, Viger RS: Novel roles for GATA transcription factors in the regulation of steroidogenesis. J Steroid Biochem Mol Biol 85:291–298 (2003b).
30.
Watanabe K, Clarke TR, Lane AH, Wang X, Donahoe PK: Endogenous expression of Mullerian inhibiting substance in early postnatal rat Sertoli cells requires multiple steroidogenic factor-1 and GATA-4-binding sites. Proc Natl Acad Sci USA 97:1624–1629 (2000).
© 2007 S. Karger AG, Basel
2007
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.